Clinical experience with PRLX93936 underscores the ceiling for systemic dosing, as a phase I trial was terminated early when patients experienced severe, intolerable toxicity at very low doses (93), revealing an exceptionally narrow therapeutic index
Presented for research literature review only LORAIZQUIERDO EC (1964)
The cytoprotective properties of Sp extended to decreased progression of degenerative phenotypes in Drosophila Parkinson model due to retention of redox balance in dopaminergic neurons and maintenance of their architecture
Tincidunt mauris, pharetra aliquam in magnis ornare sit mi velit, quis semper ut a malesuada pharetra volutpat euismod vulputate pellentesque et risus in malesuada pellentesque dictumst amet vitae vitae ut phasellus quam et enim feugiat eget mauris aenean eu volutpat, dictum donec gravida nunc egestas viverra justo sed
Demand robust evidence, be skeptical of grand claims
Beyond 6 months , ongoing maintenance therapy prevents recurrence of deficiency